Q2 2026 delivered 13% revenue growth, record new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance was raised for revenue and margins, with continued growth expected as G7 15-day adoption accelerates.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.